Linked e-resources
Details
Table of Contents
Intro
Preface
Acknowledgment
Contents
Contributors
Chapter 1: Introduction: Metrics and Domains Measured in SLE
Introduction
Core Set of Domains in SLE, Classification, and Response Criteria
Core Domain 1: Disease Activity
Core Domain 2: Chronic Damage Resulting from Lupus Activity or Its Treatment
Disease Activity and Damage in Special Circumstances: Childhood and Pregnancy
Childhood
Pregnancy
Core Domain 3: Health-Related Quality of Life
Core Domains 4: Adverse Events of Drugs
Core Domain 5: Economic Impact
Emerging Concepts in SLE and Deep Insights on Selected Concepts
Cognitive Impairment
Depression and Anxiety
Fatigue and Pain
Frailty
Instrument Selection: The OMERACT Process
Facilitating Development of Response Criteria and Classification Criteria: EULAR/ACR Collaborative Projects
Conclusion
Bibliography
Chapter 2: Clinical Aspects of Systemic Lupus Erythematosus
Introduction
Classification of SLE
General Manifestations
Cutaneous Manifestations
Acute Cutaneous Lupus
Chronic Cutaneous Lupus
Non-specific Cutaneous Lesions
Musculoskeletal Features
Lupus Myositis
Other Musculoskeletal Manifestations
Renal Manifestations
Neuropsychiatric Manifestations
Gastrointestinal Involvement
Mucocutaneous Lesions
Lupus Enteritis
Serositis
Associated Hepatobiliary Manifestations
Hematologic Manifestations
Pulmonary Involvement
Cardiac Manifestations
Accelerated Atherosclerosis
References
Chapter 3: Diagnosis and Classification of Systemic Lupus Erythematosus
Introduction
Classification Criteria Are Not Diagnostic Criteria
2019 EULAR/ACR Classification Criteria
Item Generation and New Insights About What Constitutes SLE
Phase 2. Reducing the Number of Criteria and Other Lessons Learned
Phase 3. Weighting and Threshold Identification
Phase 4. Validation
Summary
References
Chapter 4: Challenges and Advances in SLE Autoantibody Detection and Interpretation
Introduction
Important Considerations in Interpretation of ANA Test Results and Reports
Specific Autoantibodies
Chromatin Components
Double-Stranded DNA
Histones
Nucleosomes
High-Mobility Group Proteins
Dense Fine Speckled (DFS)
Preface
Acknowledgment
Contents
Contributors
Chapter 1: Introduction: Metrics and Domains Measured in SLE
Introduction
Core Set of Domains in SLE, Classification, and Response Criteria
Core Domain 1: Disease Activity
Core Domain 2: Chronic Damage Resulting from Lupus Activity or Its Treatment
Disease Activity and Damage in Special Circumstances: Childhood and Pregnancy
Childhood
Pregnancy
Core Domain 3: Health-Related Quality of Life
Core Domains 4: Adverse Events of Drugs
Core Domain 5: Economic Impact
Emerging Concepts in SLE and Deep Insights on Selected Concepts
Cognitive Impairment
Depression and Anxiety
Fatigue and Pain
Frailty
Instrument Selection: The OMERACT Process
Facilitating Development of Response Criteria and Classification Criteria: EULAR/ACR Collaborative Projects
Conclusion
Bibliography
Chapter 2: Clinical Aspects of Systemic Lupus Erythematosus
Introduction
Classification of SLE
General Manifestations
Cutaneous Manifestations
Acute Cutaneous Lupus
Chronic Cutaneous Lupus
Non-specific Cutaneous Lesions
Musculoskeletal Features
Lupus Myositis
Other Musculoskeletal Manifestations
Renal Manifestations
Neuropsychiatric Manifestations
Gastrointestinal Involvement
Mucocutaneous Lesions
Lupus Enteritis
Serositis
Associated Hepatobiliary Manifestations
Hematologic Manifestations
Pulmonary Involvement
Cardiac Manifestations
Accelerated Atherosclerosis
References
Chapter 3: Diagnosis and Classification of Systemic Lupus Erythematosus
Introduction
Classification Criteria Are Not Diagnostic Criteria
2019 EULAR/ACR Classification Criteria
Item Generation and New Insights About What Constitutes SLE
Phase 2. Reducing the Number of Criteria and Other Lessons Learned
Phase 3. Weighting and Threshold Identification
Phase 4. Validation
Summary
References
Chapter 4: Challenges and Advances in SLE Autoantibody Detection and Interpretation
Introduction
Important Considerations in Interpretation of ANA Test Results and Reports
Specific Autoantibodies
Chromatin Components
Double-Stranded DNA
Histones
Nucleosomes
High-Mobility Group Proteins
Dense Fine Speckled (DFS)